DCTH Delcath Systems Inc

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  10/23/2001
Outstanding shares:  7,356,289
Average volume:  162,465
Market cap:   $67,162,919
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    24661P807
ISIN:        US24661P8077
Valuation   (See tab for details)
PE ratio:   -2.13
PB ratio:   4.96
PS ratio:   45.91
Return on equity:   -173.20%
Net income %:   -1,388.18%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy